About us

Qureight’s mission is to accelerate clinical trials and ensure breakthroughs in lung and heart disease reach patients without delay. Our AI-powered data and imaging curation platform enables the analysis of clinical imaging and other healthcare data, helping our customers bring treatments to market, faster.

We’re looking for talented people who want their work to matter. With offices in Cambridge and London, you’ll join our multidisciplinary team of clinicians, scientists and engineers. What unites us is our open culture, continuous learning mindset and a shared mission to help biopharma run faster, smarter trials.

About the role

We are looking for a scientifically trained, commercially minded Corporate Development Associate to support Qureight’s continued growth and strategic development. Working closely with the CEO and senior leadership team, you will support major strategic initiatives, with a particular focus on developing partnerships with global pharmaceutical companies and evaluating opportunities arising from Qureight’s scientific and technology capabilities.

You will research pharmaceutical pipelines, therapeutic areas, clinical-development programmes and potential partners; assess the scientific and commercial rationale for new opportunities; and help turn these insights into clear recommendations, presentations and partnership proposals. The role sits at the intersection of science, strategy and commercial development. You will need to understand how biomarkers are developed, validated and used in clinical trials, alongside the regulatory considerations that influence their adoption.

You will work with Qureight’s clinical, scientific, product, regulatory and commercial teams to help identify opportunities where our imaging, data and AI capabilities can create meaningful value for pharmaceutical partners. You will also work closely with our CCO and CFO.

This is a strong opportunity for someone with a scientific background who wants to develop a career in corporate development, pharmaceutical partnerships and life-sciences strategy.